Pain and stiffness may not completely resolve in 20 to 50 per cent of affected people. Epidemiology
Adhesive capsulitis newly affects approximately 0.75% to 5.0% percent of people a year. Rates are higher in people with diabetes (10–46%). Following breast surgery, some known complications include loss of shoulder range of motion (ROM) and reduced functional mobility in the involved arm. Occurrence is rare in children and people under 40. with the highest prevalence between 40 and 70 years of age. The condition is more common in women than in men (70% of patients are women aged 40–60). People with diabetes, stroke, lung disease, rheumatoid arthritis, or heart disease are at a higher risk for frozen shoulder. Symptoms in people with diabetes may be more protracted than in the non-diabetic population. See also
Calcific tendinitis
Milwaukee shoulder syndrome

References


== External links ==
Contraindications
This medicine should not be used for people who have an obstructive GI or urinary condition, severe ulcerative colitis, reflux, any unstable cardiac condition, glaucoma, myasthenia gravis, and anyone who is acutely bleeding.It should not be given to children or infants with colic due to the risks of convulsions, difficult breathing, irritability, and restlessness, and there is little evidence to support the efficacy in such use in any case.Because dicycloverine is known to impair thinking and coordination, people taking the drug should avoid driving or operating machinery.The effect on the baby during pregnancy or breastfeeding is not well understood. Adverse effects
Dicycloverine can cause a range of anticholinergic side effects such as dry mouth, nausea, blurred vision, dizziness, confusion, severe constipation, stomach pain, heart palpitations, difficulty urinating, and seizures. Pharmacology
Dicycloverine blocks the action of acetylcholine on cholinergic receptors on smooth muscles in the GI tract, relaxing the smooth muscle. History
Dicycloverine was first synthesized chemically in the United States circa 1945 by scientists at William S. Merrell Company.It was first marketed in 1952 for gastrointestinal disorders, including colic in infants. The INN name "dicycloverine" was recommended in 1959. It was included in the combination drug for morning sickness called Bendectin, along with doxylamine and vitamin B6 which was launched in the US 1956; dicyclomine was removed from the formulation in 1976 after Merrell determined that it added no value.